StockNews.com initiated coverage on shares of Anika Therapeutics (NASDAQ:ANIK – Get Rating) in a report issued on Thursday morning. The brokerage issued a hold rating on the biotechnology company’s stock. Several other research firms also recently commented on ANIK. Zacks Investment Research upgraded shares of Anika Therapeutics from a sell rating to a hold rating […]
Anika Therapeutics, Inc. (NASDAQ:ANIK – Get Rating) Director Jeffery S. Thompson acquired 2,000 shares of the firm’s stock in a transaction dated Friday, March 11th. The shares were purchased at an average price of $24.66 per share, with a total value of $49,320.00. The purchase was disclosed in a filing with the SEC, which is […]
Anika Therapeutics (NASDAQ:ANIK – Get Rating) released its earnings results on Tuesday. The biotechnology company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.33), MarketWatch Earnings reports. Anika Therapeutics had a negative net margin of 3.96% and a positive return on equity of 1.63%. During the same period […]